Novartis AG (VIE:NOVN)
Austria · Delayed Price · Currency is EUR | Market Cap | 256.41B +34.6% |
| Revenue (ttm) | 49.62B +2.7% |
| Net Income | 11.17B -6.6% |
| EPS | 5.79 -3.4% |
| Shares Out | n/a |
| PE Ratio | 22.96 |
| Forward PE | 16.90 |
| Dividend | 4.10 (3.05%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | n/a |
| Open | 135.30 |
| Previous Close | 134.92 |
| Day's Range | 135.12 - 135.80 |
| 52-Week Range | 98.00 - 143.52 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 21, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
FDA Approves Novartis' Pluvicto Combo For Metastatic Hormone-sensitive Prostate Cancer
(RTTNews) - Novartis (NVS) announced that the U.S. Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for...
Novartis says FDA approves Pluvicto for PSMA+ metastatic prostate cancer
Novartis (NVS) announced the US Food and Drug Administration approved Pluvicto in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen-positive ...
Novartis chart may soon 'complete a well-defined bullish reversal,' Cappelleri says
The Swiss drugmaker reported earnings a few days ago and, so far, has done a good job holding near its recent highs.
3 Dividend Stocks to Buy for a Lifetime of Passive Income
Novartis is expertly handling massive patent cliffs, which speaks volumes about how resilient its business is. Abbott Laboratories has attractive long-term opportunities within its core medical device...
Swiss Market Index Rises as US-Iran Pause Lifts Sentiment, Defensive Pharma Giants Anchor Gains Monday
The Swiss Market Index rose as U.S.-Iran tensions eased, boosting European markets and lowering oil prices. Defensive stocks like Roche and Novartis led the gains amid ongoing geopolitical uncertainti...
Novartis price target raised to CHF 142 from CHF 132 at Citi
Citi analyst Graham Parry raised the firm’s price target on Novartis (NVS) to CHF 142 from CHF 132 and keeps a Buy rating on the shares.
Novartis (NVS) Q2 2026 Earnings Call Transcript
Growth drivers offset generic erosion as priority brands surge 36% in constant currency.
Novartis CEO on 2Q Profit Beat, Investing in Pipeline
Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong performance from its new cancer medicines which offset declining sales of its former blockbuster drug...
Novartis (NVS) Exceeds Expectations with Strong Half-Year Results
Novartis (NVS) Exceeds Expectations with Strong Half-Year Results
Novartis CEO Vas Narasimhan on Q2 earnings beat
Novartis CEO Vas Narasimhan joins CNBC's 'Squawk on the Street' to discuss the Swiss pharmaceutical company's second-quarter earnings, M&A outlook, forward guidance, and more.
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Novartis CEO Vas Narasimhan joins CNBC's 'Squawk on the Street' to discuss the Swiss pharmaceutical company's second-quarter earnings, M&A outlook, forward guidance, and more.
Novartis (NVS) Returned to Sales Growth in Q2, but the Patent-Cliff Math Still Runs the Story
Novartis AG (NVS) gave investors a better quarter in the three months ended June 30, 2026, but not a clean... The post Novartis (NVS) Returned to Sales Growth in Q2, but the Patent-Cliff Math Still Ru...
Novartis Q2 Earnings Call Highlights
Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite con...
Q2 Earnings Pick Up Steam: GM, MMM, DHI & More
GM, MMM, NVS, NOC, HAS and DHI all outperformed expectations on their quarterly reports this morning.
Novartis Bounds For Buy Point. Why Shares Are On The Rise.
Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx.
Novartis AG Earnings Call Transcript: Q2 2026
Q2 2026 saw 1% net sales growth and flat core operating income, driven by strong performance in key brands and launches, offsetting generic erosion. Full-year guidance is reaffirmed, with growth drivers showing robust momentum and multiple pivotal pipeline readouts expected in H2.
Novartis AG Quarterly report: Q2 2026
Novartis AG has published its Q2 2026 quarterly earnings report on July 21, 2026.
Novartis AG Slides: Q2 2026
Novartis AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 21, 2026.
Novartis AG Earnings release: Q2 2026
Novartis AG released its Q2 2026 earnings on July 21, 2026, summarizing the period's financial results.
HSBC says pharma remains defensive bet despite AI hype
Rajesh Kumar, Head of European Life Sciences & Healthcare Equity Research at HSBC, discusses Novartis’ half-year results and explains why the company has performed well despite AI disruption and macro...
Novartis (NVS) Projects Modest Growth in Sales and Decline in Operating Income
Novartis (NVS) Projects Modest Growth in Sales and Decline in Operating Income
Stocks making the biggest moves premarket: General Motors, 3M, Novartis, Nebius & more
These are the stocks posting the largest moves in early trading.
Novartis CEO Vas Narasimhan says 'no change of plans'
Novartis chief executive officer Vas Narasimhan said on Tuesday he plans to stick around for the Swiss drugmaker's next phase of growth, ahead of a series of high-stakes trial data expected f...
Novartis (NOVN) Reports Q2 Revenue Growth Amid Patent Challenges
Novartis (NOVN) Reports Q2 Revenue Growth Amid Patent Challenges